Intellia
Investigational CRISPR Therapy Shows Efficacy Against Transthyretin Amyloidosis in Phase I Study
The therapy works by reducing serum concentration of misfolded transthyretin protein, which leads to the life-threatening disease.
UC can still salvage its CRISPR IP rights after last week's decision, but a long-shot appeal in federal court is the only possibility for total victory.
Broad Institute Wins CRISPR Patent Interference; IP Fight Not Over
The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.
CRISPR Cross-Licensing Deal Solidifies Challengers' Alliance in Patent Battle
The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.
Despite Challenges, Omics Tools/MDx Firms Find Reasons for Optimism in Attracting Private Financing
Premium
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.